

GLAXOSMITHKLINE PLC
Form 6-K
July 26, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 26 July 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- | | |
|---------------------------------------|------------------------|
| a) Name | Philip Hampton |
| b) Position/status | Non-Executive Chairman |
| c) Initial notification/
amendment | Initial notification |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- | | |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- | | |
|--|--|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') |
|--|--|

ISIN: GB0009252882

b) Nature of the transaction Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 April 2017 to 30 June 2017.

c) Price(s) and volume(s) Price(s) Volume(s)
 £15.99 2,736.085
 n/a (single transaction)

d) Aggregated information
 Aggregated volume Price

e) Date of the transaction 2017-07-26

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Professor Sir Roy Anderson
 b) Position/status Independent Non-Executive Director

c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

b) Nature of the transaction Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 April 2017 to 30 June 2017.

c) Price(s) and volume(s) Price(s) Volume(s)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

volume(s)	£15.99	566.760
	n/a (single transaction)	

Aggregated information

d) Aggregated volume Price

e) Date of the transaction 2017-07-26

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr Vindi Banga
 b) Position/status Senior Independent Non-Executive Director

c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument
 ISIN: GB0009252882

Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 April 2017 to 30 June 2017.

b) Nature of the transaction

c) Price(s) and volume(s) Price(s) Volume(s)
 £15.99 2,267.042
 n/a (single transaction)

Aggregated information

d) Aggregated volume Price

e) Date of the transaction 2017-07-26

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Dr Vivienne Cox
 - b) Position/status Independent Non-Executive Director
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 - b) Nature of the transaction Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 April 2017 to 30 June 2017.
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.99	449,500
n/a (single transaction)	
 - d) Aggregated information
Aggregated volume Price
 - e) Date of the transaction 2017-07-26
 - f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms Lynn Elsenhans
 - b) Position/status Independent Non-Executive Director
 - c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument

American Depository Shares ('ADSs')

ISIN: US37733W1053
 - b) Nature of the transaction

Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 April 2017 to 30 June 2017.
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
\$42.29	1,169.918
n/a (single transaction)	
 - d) Aggregated information

Aggregated volume Price
 - e) Date of the transaction 2017-07-26
 - f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Dr Jesse Goodman
 - b) Position/status Independent Non-Executive Director
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument

American Depository Shares ('ADSs')

ISIN: US37733W1053

	Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 April 2017 to 30 June 2017.
b) Nature of the transaction	
c) Price(s) and volume(s)	Price(s) Volume(s) \$42.29 392.214 n/a (single transaction)

Aggregated information
d) Aggregated volume Price

e) Date of the transaction	2017-07-26
f) Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Ms Judy Lewent
b) Position/status	Independent Non-Executive Director
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	American Depositary Shares ('ADSs')
	ISIN: US37733W1053
b) Nature of the transaction	Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 April 2017 to 30 June 2017.
c) Price(s) and volume(s)	Price(s) Volume(s) \$42.29 437.038
d) Aggregated information	n/a (single transaction)

Aggregated volume Price

- e) Date of the transaction 2017-07-26
- f) Place of the transaction n/a
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr Urs Rohner
- b) Position/status Independent Non-Executive Director
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
- ISIN: GB0009252882
- b) Nature of the transaction Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 April 2017 to 30 June 2017.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|--------------------------|-----------|
| £15.99 | 566.760 |
| n/a (single transaction) | |
- d) Aggregated information
- Aggregated volume Price
- e) Date of the transaction 2017-07-26
- f) Place of the transaction n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: July 26, 2017

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc